On July 26, Haisco issued an announcement stating that its wholly-owned subsidiary, Haisco Pharmaceutical (Meishan) Co.
, had recently received the "Drug Registration Certificate" for perindopril indapamide tablets issued by the State Food and Drug Administration
The drug is indicated for the treatment of essential hypertension in adults, and is suitable for patients who cannot completely control blood pressure by taking perindopril alone
Perindopril indapamide tablets are a combination of perindopril tert-butylamine (an angiotensin converting enzyme inhibitor) and indapamide (a diuretic containing a chlorosulfamide group)
The pharmacological properties of perindopril indapamide tablets come from the respective pharmacological properties of the two components and the positive synergistic effect produced by the combined use of the two
First of all, diuretics promote sodium excretion, avoiding the increase in renal sodium retention caused by other antihypertensive drugs, and further enhance the antihypertensive effect
Second, diuretics activate the renin angiotensin system (RAS) by reducing blood volume, which can enhance the effect of RAS blockers
In addition, RAS blockers block RAS activation, which can enhance the sodium excretion of diuretics and improve the antihypertensive effect
This product regulates the renin-angiotensin system (RAS) through different pathways.
The former inhibits the activation of the RAS system, while the latter reflexively activates the RAS, which can reduce adverse reactions; and the product has a precise dosage and reasonable preparation, and only needs to be used daily.
Once, the treatment is simplified and convenient, easy for patients to accept, and can reduce missed doses
Due to the small dose and the adverse reactions cancel each other out (perindopril increases blood potassium and indapamide can reduce blood potassium), adverse reactions can be minimized
Upon inquiry, Perindopril and Indapamide Tablets were developed by LES LABORATOIRES SERVIER in France.
They were first marketed in France in 1997 and in Spain in 2003.
The marketed specification is perindopril tert-butylamine 4mg.
25mg, mainly used for essential hypertension, is suitable for patients whose blood pressure cannot be completely controlled by taking perindopril alone
Perindopril indapamide tablets produced by the original manufacturer LESLABORATOIRES SERVIER were approved to be produced by Servier (Tianjin) Pharmaceutical Co.
in 2005, and the trade name is: Bipler®
Its specifications are perindopril tert-butylamine 2mg, indapamide 0.
625mg (National Medicine Standard H20051755) and perindopril tert-butylamine 4mg, Indapamide 1.
25mg (National Medicine Standard H20051756)
Its indication is essential hypertension, which is suitable for patients whose blood pressure cannot be completely controlled by taking perindopril alone